NRXS: חוב כולל להון NeurAxis

NeurAxis, Inc. (NRXS) is strengthening its position by expanding clinical trials to adult patients, which, combined with the unwavering trust of pediatricians, minimizes market risks. The price trend reflected below serves as an indicator of the debt load, which currently stands at 0.04. The business relies on the development of non-invasive wearable systems that regulate bodily functions using electrical impulses instead of medication.

The long-term sustainability of the issuer is determined by the balance between borrowed funds and equity, reflecting the total debt-to-equity ratio as a measure of the business's dependence on creditors. This indicator allows for an assessment of the bankruptcy risk of NeurAxis, Inc., whose operational activities in developing electrical stimulation systems are accompanied by minimal costs for the environmental disposal of electronic waste.